CHESHIRE, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc., (Nasdaq: ALXN) today announced that Canada’s national healthcare regulatory agency, Health Canada, has approved the use of Soliris® (eculizumab) for the treatment of all patients in Canada with paroxysmal nocturnal hemoglobinuria (PNH), a rare, debilitating and life-threatening blood disorder defined by chronic red blood cell destruction, or hemolysis. Soliris is the first therapy approved in Canada for the treatment of PNH.
